In addition, various phases of preclinical trials are addressing the inhibition of HDAC in subjects with mutated advanced and unrespectable melanoma (ClinicalTrials.gov ID: NCT02836548, NCT02032810). The gene discussed is HDAC9; the disease is melanoma.